Last reviewed · How we verify
Eptifibatide (Integrilin)
Eptifibatide (Integrilin) is a Glycoprotein IIb/IIIa inhibitor Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction), Percutaneous coronary intervention. Also known as: Integrilin, SCH 060936, SCH 60936.
Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to platelet receptors.
Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to platelet receptors. Used for Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction), Percutaneous coronary intervention.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Eptifibatide (Integrilin) |
|---|---|
| Also known as | Integrilin, SCH 060936, SCH 60936 |
| Sponsor | Organon and Co |
| Drug class | Glycoprotein IIb/IIIa inhibitor |
| Target | Glycoprotein IIb/IIIa receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Eptifibatide reversibly binds to the glycoprotein IIb/IIIa receptor on platelet surfaces, inhibiting the final common pathway of platelet aggregation. By blocking fibrinogen and von Willebrand factor from cross-linking platelets, it prevents thrombus formation. This mechanism reduces ischemic complications in patients undergoing percutaneous coronary intervention or those with acute coronary syndromes.
Approved indications
- Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction)
- Percutaneous coronary intervention
Common side effects
- Bleeding
- Thrombocytopenia
- Hypotension
- Bradycardia
Key clinical trials
- Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis (PHASE3)
- Multi-arm Optimization of Stroke Thrombolysis (PHASE3)
- EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) (PHASE3)
- Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic (PHASE1, PHASE2)
- Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
- Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention (PHASE2)
- Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel (PHASE2)
- Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eptifibatide (Integrilin) CI brief — competitive landscape report
- Eptifibatide (Integrilin) updates RSS · CI watch RSS
- Organon and Co portfolio CI
Frequently asked questions about Eptifibatide (Integrilin)
What is Eptifibatide (Integrilin)?
How does Eptifibatide (Integrilin) work?
What is Eptifibatide (Integrilin) used for?
Who makes Eptifibatide (Integrilin)?
Is Eptifibatide (Integrilin) also known as anything else?
What drug class is Eptifibatide (Integrilin) in?
What development phase is Eptifibatide (Integrilin) in?
What are the side effects of Eptifibatide (Integrilin)?
What does Eptifibatide (Integrilin) target?
Related
- Drug class: All Glycoprotein IIb/IIIa inhibitor drugs
- Target: All drugs targeting Glycoprotein IIb/IIIa receptor
- Manufacturer: Organon and Co — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction)
- Indication: Drugs for Percutaneous coronary intervention
- Also known as: Integrilin, SCH 060936, SCH 60936
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing